Clinical trials in the NAPWA database are listed below - the most recently-added entries are shown at the top of the list. Click the trial name for more information about that trial.
A treatment regimen containing one protease inhibitor (PI) and two nucleoside/nucleotide reverse transcriptase inhibitors ('nucleosides' or NRTIs) is standard practice these days. While this 'PI+2NRTI' combination is very good at suppressing the virus it can also cause some major side effects. Significantly, PIs have been associated with cardiovascular disease (heart attack) and NRTIs with mitochondrial toxicity (see background info).
A treatment regimen consisting of one non-nucleoside (1NNRTI) and two nucleosides (2NRTIs) has become the internationally accepted first-line therapy of choice. But affective as the combination is, it doesn't work for everyone. And those it fails need a reliable back-up. At the moment there is no "internationally accepted" second-line.
This is a phase 2 trial to determine the safety and efficacy of an anti-HIV-1 gene transfer product.
This study is testing whether taking 800mg of darunavir once-a-day is as effective as taking 600mg of darunavir twice-a-day. (Both doses will be boosted with 100mg of ritonavir).
Participants will also take an individually selected optimised background regimen. This trial is looking for people who are currently on treatments.
This study is looking at a new drug - SCH 532706 - from the new class of CCR5 inhibitors or antagonists.
SCH 532706 is taken twice daily (with a low dose of ritonavir taken once daily) over 10 days. The purpose is to look at how effective the combination is at suppressing HIV as well as how safe and easy it is to take.
This study will compare the effect of the new integrase inhibitor, raltegravir, with that of low-dose ritonavir on triglyceride and lipid (fat) levels. Volunteers who don't have HIV will be given either 100mg of ritonavir once a day or 400mg of raltegravir twice a day for 4 weeks.
This trial is providing people who have limited treatment options open to them access to maraviroc until it offically becomes available. In the process, the trial will collect more safety data on the drug.
This study is following a large group of people with acute hepatitis C virus (HCV) to examine why some people naturally clear the virus and some don't. It will also monitor how many people become re-infected after clearing HCV and look into why this happened.
Three months into the study, everyone taking part has the option to undergo a six month course of pegylated interferon alfa 2a (plus ribavirin for those coinfected with HIV) as treatment for their hepatitis C. The purpose of this part of the study is to examine whether treatment is effective in clearing HCV.
This study was going to look at the benefits of adding T-20 to people's existing regimens, but recruitment was too slow so the study has been cancelled. Participants were to be randomized to receive T-20 in addition to their current antiretroviral therapy or to continue their current antiretroviral therapy alone.
The purpose of the study is to compare the effectiveness of 3 different treatment regimens in reducing or clearing the Hepatitis B Virus in patients infected with HIV and Hepatitis B (co-infection)
The purpose of these studies is to investigate the efficacy, safety, and tolerability of raltegravir - a new drug from the new class of integrase inhibitors. These studies will compare a raltegravir-based regimen with a lopinavir-based one.
This study is looking at how our immune system functions when we are coinfected with both HIV and either hepatitis B or C.
It might show us how some people can clear hepatitis from their system when they're on treatment while others can when they're not.
We know that adherence is important for treatment success, so this study compares a once-a-day regimen with a twice-a-day one.
It is desirable to obtain extended follow up data on subjects who participated in the 2NN study and the CHARM study in order to see if the beneficial effect of using nevirapine continues up to 144 weeks of treatment.
This is a trial for a new antiretroviral called apricitabine - an experimental nucleoside reverse transcriptase inhibitor for people who are resistant to other NRTIs, and who have the M184V mutation.
This study will look at how safe, easy to take and effective apricitabine is in people who are resistant to 3TC. If successful, it is hoped to use it as an alternative.
This information was retrieved from the Treataware website (www.treataware.info) on 2 Sep 2008. For further information, please consult the website or call the NAPWA office on 02 8568 0300.